Measurement of DPD and TS Transcripts Aimed to Predict Clinical Benefit from Fluoropyrimidines: Confirmation of the Trend in Russian Colorectal Cancer Series and Caution Regarding the Gene Referees

Publisher： Karger

E-ISSN： 2296-5262|30|6|295-300

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.30, Iss.6, 2007-05, pp. : 295-300

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan

By  

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 80, Iss. 3, 2015-09 ,pp. : 581-588

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical validity of a DPYD‐based pharmacogenetic test to predict severe toxicity to fluoropyrimidines

By  

INTERNATIONAL JOURNAL OF CANCER, Vol. 137, Iss. 12, 2015-12 ,pp. : 2971-2980

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinicopathological predictors of benefit from adjuvant chemotherapy for stage C colorectal cancer: Microsatellite unstable cases benefit

By  

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, Vol. 11, Iss. 4, 2015-12 ,pp. : 343-351

John Wiley & Sons Inc

Access to resources Recommend Favorite

Do hENT1 and RRM1 predict the clinical benefit of gemcitabine in pancreatic cancer?

By Jordheim Lars Petter   Dumontet Charles  

Biomarkers in Medicine, Vol. 7, Iss. 4, 2013-08 ,pp. : 663-671

Future Medicine

Access to resources Recommend Favorite

Trend of colorectal cancer in Hong Kong: 1983–2006

By  

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol. 25, Iss. 5, 2010-05 ,pp. : 923-927

John Wiley & Sons Inc

Access to resources Recommend Favorite